AstraZeneca to present AZD6234 data this fall as elecoglipron enters Phase 3

AstraZeneca is expected to present results for its experimental amylin drug AZD6234 at a major diabetes conference this fall, and analysts expect two more mid-stage readouts from the company's obesity pipeline before the end of 2026 ^[1].

Analysts at William Blair expect the AZD6234 data at the European Association for the Study of Diabetes annual meeting, scheduled for Sept. 28 to Oct. 2 in Italy ^[1]. AZD6234 is a selective amylin receptor peptide agonist, a mechanism that differs from the GLP-1 medicines now on the market, including semaglutide (Ozempic, Wegovy and Rybelsus) and tirzepatide (Mounjaro and Zepbound) ^[1]. Detailed Phase 2 results for AZD6234 have not been released ^[1].

William Blair also expects results during the rest of 2026 from a Phase 2 trial of AZD6234 in people with overweight or obesity and type 2 diabetes who are already on stable background GLP-1 therapy, and from the Phase 2b ASCEND study, which tests AZD6234 combined with AZD9550, a GLP-1/glucagon dual agonist, in obesity ^[1]. The add-on study is designed to test the amylin drug in people already taking a GLP-1 medicine rather than as a first treatment ^[1].

AstraZeneca has also moved its oral GLP-1 drug elecoglipron into a Phase 3 trial in obesity and type 2 diabetes, and the drug is in a separate late-stage study in type 2 diabetes alone ^[1]. William Blair expects those trials to read out in 2027 or 2028 ^[1]. Chief Executive Pascal Soriot said in February, on a media call about the company's full-year 2025 earnings, that elecoglipron has "a very competitive profile" ^[1]. Detailed results for elecoglipron have not been disclosed ^[1].

The competition reflects the size of the market. Obesity medicines generated $66 billion in sales last year and could reach between $105 billion and $200 billion by 2027 and beyond, according to IQVIA ^[1]. AstraZeneca is among the companies competing for position behind market leaders Eli Lilly and Novo Nordisk ^[1]. AstraZeneca's pipeline page lists 183 projects, including 116 new molecular entities or major life-cycle projects in Phase II or Phase III, as of July 27, 2026 ^[2]. Other amylin drugs in development include Roche's petrelintide, which Roche is testing with partner Zealand Pharma ^[1].

Why it matters for patients

Neither AZD6234 nor elecoglipron is approved for any use, and AstraZeneca has not announced an approval timeline for either one ^[1]. The AZD6234 results expected this fall come from Phase 2 trials, which are mid-stage studies and not the last step before a regulatory decision ^[1].

For people who already take a GLP-1 medicine, one of the studies now reading out tests AZD6234 in people with overweight or obesity and type 2 diabetes who are on stable background GLP-1 therapy ^[1]. That means researchers are looking at the drug as an addition to a treatment patients already take ^[1].

On the pill side, the oral GLP-1 options now on the market include Foundayo (orforglipron) and an oral version of Wegovy (semaglutide) ^[1]. Novo Nordisk's oral Wegovy accounted for about 90% of weekly oral prescriptions as of July, or roughly 1.5 million people ^[1]. Elecoglipron is another oral candidate, but with Phase 3 readouts expected in 2027 or 2028, it is years from any possible market ^[1].

What happens next

• Sept. 28 to Oct. 2: The European Association for the Study of Diabetes annual meeting in Italy, where AZD6234 data are expected ^[1].
• By the end of 2026: Expected results from the Phase 2 trial of AZD6234 in people on stable background GLP-1 therapy and from the Phase 2b ASCEND study of AZD9550 plus AZD6234 in obesity ^[1].
• 2027 or 2028: William Blair's expected timing for Phase 3 readouts of elecoglipron in obesity and type 2 diabetes ^[1].